Entities / Company
Fresenius Kabi.
company based in Bad Homborg, Germany; offers health products for the critically and chronically ill.
- Reports this week
- 0
- Active events
- 0
- Connections
- 19
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
-
Testimony regarding patent practices influences drug pricing within the U.S. pharmaceutical industry.Some support1 report
-
Fresenius Kabi received regulatory approvals from the EMA and FDA for a vedolizumab biosimilar, while excluding commercialization in the Middle East and North Africa.Some support1 report
Gone quiet
No new reports in 90+ days-
Companies ICU Medical, Fresenius Kabi, Baxter, and Codan are noted as key players in a market where Germany holds the largest market share.Some support1 report
-
Fresenius Kabi acquired a majority stake in mAbxience, which subsequently received European Commission approval for its biosimilars.Speculative1 report
-
Fresenius Kabi received an award announcement in Lake Zurich, Illinois.Some support1 report
-
Fresenius Kabi is involved in shaping the future of healthcare across Southeast Asia.Some support1 report
-
Fresenius Kabi, Charles River Laboratories, Intertek, and Gea were listed in a market report profile.Some support1 report
-
Litigation over patents and generics is ongoing, and DOMA Perpetual Capital Management holds 7.5% of Pacira's outstanding shares.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Fresenius Kabi this week
News at the entities that move Fresenius Kabi most-
European Medicines Agency TransactionalBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves Fresenius Kabi
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Fresenius Kabi
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Fresenius Kabi
-
BioPharma StructuralBioPharma and Milestone Pharmaceuticals are small-cap healthcare companies.Moves Fresenius Kabi
-
Middle East OperationalAuthorities are investigating an incident at a base in Fairford, with possible links to Iran and Russia.Moves Fresenius Kabi
-
Spain Shared contextSpain's Sira Rego made controversial remarks about the Palestinian state, leading Israel to summon the Spanish embassy and expel diplomats from Ramallah.Moves Fresenius Kabi
Connections
The 7 strongest of 19, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
European Medicines Agency Transactional
EMA accepted the Marketing Authorization Application (MAA) for the vedolizumab biosimilar product associated with Fresenius Kabi.
-
FDA Structural
The FDA granted regulatory approval for a vedolizumab biosimilar manufactured by Fresenius Kabi.
-
BioPharma Structural
Fresenius Kabi employs the President of BioPharma, indicating a formal organizational link.
-
Middle East Operational
Fresenius Kabi has excluded the Middle East from its commercialization rights.
-
Spain Shared context
The company maintains operational facilities in Spain as part of its European market presence.
-
Morgan Stanley Operational
Morgan Stanley issued an overweight rating on the shares of Fresenius Kabi.
-
North Africa Transactional
Fresenius Kabi has made a business decision to exclude North Africa from its commercialization rights.
History
Events by the month they beganAugust 2026
1 eventJune 2026
6 events- Companies ICU Medical, Fresenius Kabi, Baxter, and Codan are noted as key players in a market where Germany holds the largest market share.
- Fresenius Kabi acquired a majority stake in mAbxience, which subsequently received European Commission approval for its biosimilars.
- Fresenius Kabi received an award announcement in Lake Zurich, Illinois.
- Fresenius Kabi is involved in shaping the future of healthcare across Southeast Asia.
- Fresenius Kabi, Charles River Laboratories, Intertek, and Gea were listed in a market report profile.
- Litigation over patents and generics is ongoing, and DOMA Perpetual Capital Management holds 7.5% of Pacira's outstanding shares.